
    
      The primary objective is to establish bioequivalence of "ritonavir boosted generic GPO
      saquinavir", with Invirase® and Norvir® as the reference drug.

      The secondary objective is to evaluate the short-term tolerability and safety profiles of
      generic saquinavir in healthy male volunteers.
    
  